News
Cell and gene therapy industry continues to expand manufacturing infrastructure in the UK
The Cell and Gene Therapy Catapult, an independent innovation and technology organisation committed to the advancement of cell and gene therapies has released its Good Manufacturing Practice (GMP) Report 2024. It highlights continued growth in manufacturing infrastructure for advanced therapies, with 32 MHRA-licensed GMP manufacturing facilities in the UK, an increase from 28 last year.